Onglyza (Saxagliptin)

Saxagliptin, the active ingredient in Onglyza, is a DPP‑4 inhibitor presented as a strength/form for oral use. It is used to improve blood sugar control in adults with type 2 diabetes mellitus. GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Saxagliptin is a DPP‑4 inhibitor that targets the incretin pathway to help manage blood glucose levels.

- Type 2 Diabetes Mellitus: Improves glycaemic control as an adjunct to diet and exercise. - Combination Therapy with Metformin: Enhances overall glucose‑lowering effect when added to metformin. - Combination Therapy with a Sulfonylurea: Provides additional blood‑sugar reduction for patients not achieving targets on a sulfonary ​​  .